Trial Profile
A study predicting clinical outcome in metastatic colorectal cancer patients receiving TAS-102 and regorafenib as control.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2018
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Regorafenib
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium